

60 Rec'd PCT/PTO 06 MAR 2003

FORM PTO-1390 (Modified) (REV 5-93) U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 017227/0157
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U S APPLICATION NO. (If known, see 37 CFR 1.48) Unassigned 097486703
INTERNATIONAL APPLICATION NO. PCT/AU98/00723	INTERNATIONAL FILING DATE September 4, 1998	PRIORITY DATE CLAIMED September 5, 1997
TITLE OF INVENTION A METHOD OF DIAGNOSIS		
APPLICANT(S) FOR DO/EO/US Ian Ross DOYLE, Andrew David Bersten and Terence Evan NICHOLAS		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>		
Items 11. to 16. below concern other document(s) or information included:		
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>		

U.S. APPLICATION NO. (Unknown, See 37 CFR 1.50) Unassigned	INTERNATIONAL APPLICATION NO PCT/AU98/00723	ATTORNEY'S DOCKET NUMBER 017227/0157																																																																																																																																							
17. <input checked="" type="checkbox"/> The following fees are submitted:		CALCULATIONS PTO USE ONLY																																																																																																																																							
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO \$840.00																																																																																																																																									
International preliminary examination fee paid to USPTO (37 CFR 1.482) \$670.00																																																																																																																																									
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$690.00																																																																																																																																									
Neither international preliminary examination fee (37 CFR 1.482) nor International search fee (37 CFR 1.445(a)(2)) paid to USPTO \$970.00																																																																																																																																									
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$96.00																																																																																																																																									
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$970.0																																																																																																																																							
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))																																																																																																																																									
<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; padding: 2px;">Claims</th> <th style="text-align: left; padding: 2px;">Number Filed</th> <th style="text-align: left; padding: 2px;">Included in Basic Fee</th> <th style="text-align: left; padding: 2px;">Extra Claims</th> <th style="text-align: left; padding: 2px;">Rate</th> <th style="text-align: left; padding: 2px;"></th> </tr> </thead> <tbody> <tr> <td style="padding: 2px;">Total Claims</td> <td style="padding: 2px;">14</td> <td style="padding: 2px;">-</td> <td style="padding: 2px;">20</td> <td style="padding: 2px;">= 0</td> <td style="padding: 2px;">x \$18.00</td> </tr> <tr> <td style="padding: 2px;">Independent Claims</td> <td style="padding: 2px;">8</td> <td style="padding: 2px;">-</td> <td style="padding: 2px;">3</td> <td style="padding: 2px;">= 5</td> <td style="padding: 2px;">x \$78.00</td> </tr> <tr> <td colspan="4" style="padding: 2px;">Multiple dependent claim(s) (if applicable)</td> <td colspan="2" style="padding: 2px; text-align: right;">\$260.00</td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">TOTAL OF ABOVE CALCULATIONS =</td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">\$1360.00</td> </tr> <tr> <td colspan="6" style="padding: 2px;"> Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28). </td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">SUBTOTAL =</td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">\$1360.00</td> </tr> <tr> <td colspan="6" style="padding: 2px;"> Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)). + </td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">TOTAL NATIONAL FEE =</td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">\$1360.00</td> </tr> <tr> <td colspan="6" style="padding: 2px;"> Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + </td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">TOTAL FEES ENCLOSED =</td> </tr> <tr> <td colspan="6" style="padding: 2px; text-align: right;">\$1360.00</td> </tr> <tr> <td colspan="5"></td> <td style="text-align: right; padding: 2px;">Amount to be: refunded \$</td> </tr> <tr> <td colspan="5"></td> <td style="text-align: right; padding: 2px;">charged \$</td> </tr> <tr> <td colspan="6"> a. <input checked="" type="checkbox"/> A check in the amount of \$1360.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$1360.00 to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u>. A duplicate copy of this sheet is enclosed. </td> </tr> <tr> <td colspan="6"> NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status. </td> </tr> <tr> <td colspan="6"> SEND ALL CORRESPONDENCE TO: Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109 </td> </tr> <tr> <td colspan="6" style="text-align: right; padding-top: 10px;">  SIGNATURE <hr/> NAME STEPHEN A. BENT </td> </tr> <tr> <td colspan="6" style="text-align: center; padding-top: 10px;"> REGISTRATION NUMBER 29,768 </td> </tr> </tbody></table>						Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate		Total Claims	14	-	20	= 0	x \$18.00	Independent Claims	8	-	3	= 5	x \$78.00	Multiple dependent claim(s) (if applicable)				\$260.00		TOTAL OF ABOVE CALCULATIONS =						\$1360.00						Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).						SUBTOTAL =						\$1360.00						Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)). +						TOTAL NATIONAL FEE =						\$1360.00						Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						TOTAL FEES ENCLOSED =						\$1360.00											Amount to be: refunded \$						charged \$	a. <input checked="" type="checkbox"/> A check in the amount of \$1360.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$1360.00 to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.						NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.						SEND ALL CORRESPONDENCE TO: Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109						 SIGNATURE <hr/> NAME STEPHEN A. BENT						REGISTRATION NUMBER 29,768					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate																																																																																																																																					
Total Claims	14	-	20	= 0	x \$18.00																																																																																																																																				
Independent Claims	8	-	3	= 5	x \$78.00																																																																																																																																				
Multiple dependent claim(s) (if applicable)				\$260.00																																																																																																																																					
TOTAL OF ABOVE CALCULATIONS =																																																																																																																																									
\$1360.00																																																																																																																																									
Reduction by ½ for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).																																																																																																																																									
SUBTOTAL =																																																																																																																																									
\$1360.00																																																																																																																																									
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)). +																																																																																																																																									
TOTAL NATIONAL FEE =																																																																																																																																									
\$1360.00																																																																																																																																									
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +																																																																																																																																									
TOTAL FEES ENCLOSED =																																																																																																																																									
\$1360.00																																																																																																																																									
					Amount to be: refunded \$																																																																																																																																				
					charged \$																																																																																																																																				
a. <input checked="" type="checkbox"/> A check in the amount of \$1360.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$1360.00 to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.																																																																																																																																									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.																																																																																																																																									
SEND ALL CORRESPONDENCE TO: Foley & Lardner Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5109																																																																																																																																									
 SIGNATURE <hr/> NAME STEPHEN A. BENT																																																																																																																																									
REGISTRATION NUMBER 29,768																																																																																																																																									

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ian R. DOYLE et al

Title: A METHOD OF DIAGNOSIS

Appl. No.: Unassigned

Filing Date: March 6, 2000

Examiner: Unassigned

Art Unit: Unassigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination, Applicants respectfully request that the above-identified application be amended as follows:

In the Claims:

Please cancel claims 9-12, 14-18, 23-27, and 31-35, and amend the following claims.

Claim 1, line 1, insert after mammal --,--.

Claim 5, line 1, delete "any one of claims 1 to 4" and insert --claim 1--.

Claim 7, line 1, delete "any one of claims 1 to 6" and insert --claim 1--.


Claim 36, line 1, insert after samples --,--.

REMARKS

Entry of the foregoing amendments prior to examination is respectfully requested.

Applicants respectfully request that the foregoing amendments to Claims 5 and 7, be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims.

Respectfully submitted,

By 

Date March 6, 2000

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768

09/486703

402 Rec'd PCT/PTO 6 MAR 2000

A METHOD OF DIAGNOSIS**FIELD OF THE INVENTION**

5 The present invention relates generally to a method of diagnosing or predicting the development of lung damage and more particularly, to a method of diagnosing or predicting the development of alveolo-capillary membrane damage. The method of the present invention is useful *inter alia* for detecting lung damage or predicting the development of lung damage such as that caused by noxious agents or as an undesirable side effect resulting from exposure
10 to a therapeutic agent and for monitoring the progress of lung damage.

BACKGROUND OF THE INVENTION

The bibliographic details of the publications referred to by author in the specification are
15 collected at the end of the description.

The gas/liquid interface of the lung is lined with a monomolecular layer comprising phospholipid, neutral lipids and specific proteins (surfactant proteins A, B, C and D, herein referred to as SP-A, -B, -C and -D, respectively). Collectively known as "pulmonary surfactant", these compounds lower surface tension, decrease the work of breathing, and stabilise the lung by varying surface tension allowing alveoli of different sizes to co-exist.
20

Pulmonary surfactant phospholipids are synthesised by Alveolar Type II cells where they are stored in distinctive vesicles known as lamellar bodies. In response to a variety of stimuli, 25 in particular physical distortion of the type II cells, the contents of the lamellar bodies are released into the hypophase, where they hydrate to form a 3-D lattice structure known as tubular myelin. The tubular myelin in turn supplies the monomolecular layer at the gas/liquid interface that possesses the biophysical activity.

- 2 -

The components of the monomolecular layer have a defined life and are constantly replaced. The disaturated phospholipids (DSP) are credited with reducing surface tension to the very low values thought to occur at low lung volumes, while cholesterol, the second most abundant pulmonary surfactant lipid, is thought to affect the rate of adsorption and the fluidity of newly released material. The system is extremely dynamic; in rats, dipalmitoylphosphatidylcholine, the main component of mammalian pulmonary surfactant, has a half-life of ~85 minutes in the alveolus with as much as 85% taken back into type II cells and reutilised (Nicholas *et al.*, 1990).

10 To date, four proteins, SP-A, -B, -C and -D have been shown to be uniquely associated with mammalian pulmonary surfactant. There is a general consensus that the extremely hydrophobic proteins (SP-B and -C) are functional components of the monomolecular layer, whereas the more hydrophilic protein, SP-A appears to be more involved in pulmonary surfactant homeostasis and host defence, and SP-D is solely involved in host defence.

15 The adult respiratory distress syndrome (ARDS) represents a severe, diffuse lung injury caused by either direct, via the airways, or indirect, via the blood, trauma. The hallmark of ARDS is a deterioration in blood oxygenation and respiratory system compliance as a consequence of permeability edema. Whereas a variety of different insults may lead to 20 ARDS, a common pathway probably results in the lung damage. Leukocyte activation within the lung, along with the release of oxygen free radicals, arachidonic acid metabolites, and inflammatory mediators such as interleukin-1, proteases, and tumour necrosis factor results in an increase in alveolo-capillary membrane permeability. With the loss of this macromolecular barrier, alveoli are flooded with serum proteins, which impair the function 25 of pulmonary surfactant (Said *et al.*, 1965; Holm *et al.*, 1987). This creates hydrostatic forces that further exacerbates the condition (Jefferies *et al.*, 1988), leading to alveolar edema and a concomitant deterioration in gas exchange and lung compliance.

- 3 -

In the last decade, numerous methods for determining lung permeability have been assessed (Staub *et al.* 1990). Generally, these have relied upon detecting flux of radiolabels into, or out of, the lung. However, few have been applied clinically because of logistic problems with suitable scanners, stability, and specificity of the labels, and uncertainty over 5 mathematical modelling (Staub *et al.* 1990). Further, lung damage, such as that induced by a noxious agent, has only been clinically detectable when sufficient damage has occurred for there to be changes in airway resistance or gas exchange. It is well accepted that this reflects relatively advanced lung disease.

10 Surfactant proteins are normally only found in appreciable amounts in the lung. In the airspaces, SP-A predominantly forms high molecular weight oligomers (~650 kDa) with Stokes radii of ~35 nm (Voss *et al.*, 1988). Although mature SP-B, which associates as a low M_r (~18 kDa) thiol dependent homo-dimer (Johansson *et al.*, 1991), is normally intimately associated with complexes of surfactant phospholipid, (Longo *et al.*, 1992), invitro and in
15 vivo studies in isolated type II cells suggest that at least some of the protein is secreted into the alveolus as hydrophilic, monomeric proprotein and processing intermediate with M_r of ~45 kDa and ~25 kDa, respectively (Weaver and Whitsett, 1989; Doyle *et al.*, 1997).

In work leading up to the present invention, the inventors have unexpectedly found that serum
20 pulmonary surfactant levels provide an extremely sensitive diagnostic marker of either lung damage, and in particular early stage lung damage, or a predisposition to the development of lung damage.

SUMMARY OF THE INVENTION

25

Throughout the specification, unless the context required otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

- 4 -

Accordingly, one aspect of the present invention relates to a method of diagnosing lung damage in a mammal, said method comprising screening for the modulation of pulmonary surfactant levels in the body fluid of said mammal.

5 In another aspect there is provided a method of diagnosing lung damage in a mammal, said method comprising screening for the modulation of one or more of SP-A, -B, -C or -D levels in the blood of said mammal.

Yet another aspect of the present invention relates to a method of diagnosing lung damage in
10 a mammal said method comprising screening for the modulation of SP-B levels in the blood of said mammal.

In yet another aspect of the present invention there is provided a method of diagnosing early stage lung damage in a mammal, said method comprising screening for the modulation of
15 pulmonary surfactant levels in the blood of said mammal.

Still yet another aspect of the present invention a method of detecting early stage lung damage in a mammal, said method comprising screening for the modulation of SP-B levels in the blood of said mammal.

20 In still another aspect of the present invention there is provided a method of diagnosing early stage alveolo-capillary membrane damage in a mammal, said method comprising screening for an increase in SP-B levels in the blood of said mammal.

25 A further aspect of the present invention provides a method of monitoring for changes in the extent of lung damage in a mammal said method comprising screening for the modulation of pulmonary surfactant levels in the blood of said mammal.

- 5 -

In another further aspect of the present invention there is provided a method of monitoring for an increase in the extent of alveolo-capillary membrane damage in a mammal said method comprising screening for an increase in SP-B levels in the blood of said mammal.

5 Yet another further aspect of the present invention provides a method of monitoring for a decrease in the extent of alveolo-capillary membrane damage in a mammal said method comprising screening for a decrease in SP-B levels in the serum of said mammal.

Accordingly, another aspect of the present invention relates to a method of diagnosing lung
10 damage in a mammal, said method comprising screening of the modulation of pulmonary surfactant level ratios in the blood of said mammal.

Yet another aspect of the present invention relates to a method of monitoring for changes in the extent of lung damage in a mammal, said method comprising screening for the modulation
15 of pulmonary surfactant level ratios in the blood of said mammal.

In yet another further aspect of the present invention there is provided a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage, said method comprising screening for the modulation of pulmonary
20 surfactant levels in the blood of said mammal wherein the levels of said pulmonary surfactant are indicative of a predisposition to developing additional lung damage.

Still yet another further aspect of the present invention provides a method of determining, in a mammal which has developed ALI due to exposure to a lung injury factor, a predisposition
25 to developing ARDS said method comprising screening for the modulation of pulmonary surfactants in the blood of said mammal wherein the levels of said pulmonary surfactant are indicative of a predisposition to developing ARDS.

In still yet another further aspect of the present invention this is provided a method of determining, in a mammal which has developed ALI due to exposure to a lung injury factor, a predisposition to the development of ARDS said method comprising screening for the level of SP-A and/or SP-B in the blood of said mammal wherein the level of said SP-A and/or SP-B is indicative of a predisposition to developing ARDS.

Yet another aspect of the present invention provides a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage said method comprising screening for the modulation of pulmonary surfactant level ratios in the blood of said mammal wherein said ratios are indicative of a predisposition to developing severe lung damage.

Another aspect of the present invention provides a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage said method comprising correlating the modulation of pulmonary surfactant levels in the body fluid of said mammal with the measurement result of another lung clinical parameter wherein the result of said correlation is indicative of a predisposition to developing severe lung damage.

In another aspect the present invention provides a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage said method comprising correlating the modulation of pulmonary surfactant levels in the body fluid of said mammal with the lung injury score wherein the result of said correlation is indicative of a predisposition to developing severe lung damage.

25 Yet another aspect of the present invention provides a diagnostic kit for assaying serum samples comprising in compartmental form a first compartment adapted to contain an agent for detecting pulmonary surfactant and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment. Further compartments may also be included, for example, to receive a biological sample. The agent may be an antibody
30 or other suitable detecting molecule.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated, in part on the identification of a correlation between serum pulmonary surfactant levels and diagnosis of the development or predisposition to the 5 development of lung damage.

Accordingly, one aspect of the present invention relates to a method of diagnosing lung damage in a mammal, said method comprising screening for the modulation of pulmonary surfactant levels in the body fluid of said mammal.

10

Reference to "body fluid" should be understood to include reference to fluids derived from the body of said mammal such as, but not limited to, blood (including all blood derived components, for example, serum and plasma), urine, tears, bronchial secretions or mucus and fluids which have been introduced into the body of said mammal and subsequently removed such as, for example, the saline solution extracted from the lung following lung lavage. Preferably, the body fluid is blood or urine and even more preferably blood. Reference hereinafter to blood should be read as including reference to all other body fluids.

The term "mammal" as used herein includes humans, primates, livestock animals (e.g. horses, cattle, sheep, pigs, donkeys), laboratory test animals (e.g. mice, rats, rabbits, guinea pigs), companion animals (e.g. dogs, cats) and captive wild animals (e.g. kangaroos, deer, foxes). Preferably, the mammal is a human or a laboratory test animal. Even more preferably, the mammal is a human. The term "lung damage" encompasses, but is not limited to, lung damage due to, for example, a congenital abnormality or an acquired abnormality such as that due to the on-set of an autoimmune condition, post-transplant lung rejection, infections resulting in an inflammatory response, changes in pressure/volume relationships in the lung, exposure of said mammal to a foreign agent (for example cigarette smoke or dust), a noxious or toxic agent (for example solvents or fumes) or is an undesirable side effect resulting from exposure to a therapeutic agent. Examples of lung damage include, but are not limited to, morphological/structural damage and/or damage to the functioning of the lung.

such as, for example, accumulation of proteins (for example surfactant) or fluids due to pulmonary clearance impairment or damage to the pulmonary gaseous exchange mechanisms. In a particular embodiment of the present invention said lung damage is alveolo-capillary membrane damage.

5

Reference herein to "pulmonary surfactant" should be read as including reference to all forms of pulmonary surfactant and derivatives thereof including but not limited to pulmonary phospholipid, pulmonary neutral lipids and pulmonary surfactant proteins, and includes all subunit molecules including, by way of example, the precursor, proproteins, proprotein 10 and intermediate forms of SP-B. Examples of pulmonary surfactant proteins include SP-A, -B, -C and -D. Preferably, said pulmonary surfactant is SP-A, -B, -C or -D. Reference herein to "SP-A" "SP-B", "SP-C" and "SP-D" should be understood to include reference to all forms of these molecules including all precursor, proprotein and intermediate forms thereof.

15

Accordingly, there is provided a method of diagnosing lung damage in a mammal, said method comprising screening for the modulation of one or more of SP-A, -B, -C or -D levels in the blood of said mammal.

20 Levels of circulating SP-A and SP-B depend not only on the relative sizes of the proteins and lung permeability but also the form available to breach the membrane barriers. SP-A binds phospholipid avidly to the extent that there is little of it free in alveoli fluid. In contrast, the predominant form of alveolar immunoreactive SP-B, proprotein and processing intermediate are not bound to surface lipids, possibly allowing freer entry into circulation. Further, that 25 the plasma SP-B/SP-A ratio varies with lung function suggests that plasma SP-B is a more dynamic marker of changes in lung permeability than is SP-A.

In a most preferred embodiment, the present invention relates to a method of diagnosing lung damage in a mammal said method comprising screening for the modulation of SP-B levels in 30 the blood of said mammal.

In a particular aspect, said lung damage may be alveolo-capillary membrane damage.

"Derivatives" of said surfactants includes fragments, parts, portions, mutants and analogs thereof. Derivatives may be derived from insertion, deletion or substitution of an amino acid.

5 Amino acid insertional derivatives include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acids. Insertional amino acid sequence variants are those in which one or more amino acid residues are introduced into a site in the protein. Deletional variants are characterised by the removal of one or more amino acids from the sequence. Substitutional amino acid variants are those in which at least one residue
10 in the sequence has been removed and a different residue inserted in its place.

The method of the present invention is particularly useful in detecting early stage lung damage. "Early stage" is defined as the period during which the onset and development of lung damage is undetectable or else cannot be confirmed without the aid of one or more
15 invasive procedures. For example, the method of this invention has application in detecting early changes in lung permeability in smokers. "Early stage" should also be understood to include low levels of lung damage such as for example, mild but chronic lung damage. Early changes in lung permeability which may be associated with neutrophil recruitment and initial destruction of lung connective tissue by elastase and reactive oxygen species may be marked
20 by an increase in plasma SP-B levels despite the absence outwardly of any visible symptoms of lung damage.

Accordingly, there is provided a method of diagnosing early stage lung damage in a mammal, said method comprising screening for the modulation of pulmonary surfactant levels in the
25 blood of said mammal.

Preferably said pulmonary surfactant is SP-A, -B, -C or -D and even more preferably SP-B.

- 10 -

In a most preferred embodiment there is provided a method of detecting early stage lung damage in a mammal, said method comprising screening for the modulation of SP-B levels in the blood of said mammal.

5 In particular, said lung damage may be alveolo-capillary membrane damage.

Although not intending to limit the invention to any one theory or mode of action, alveolo-capillary membrane damage causes an increase in alveolo-capillary permeability. Although immunoreactive SP-A and SP-B are not normally present in appreciable amounts in the 10 systemic circulation, it is thought that the appearance of additional pulmonary surfactant proteins in the serum of patients with lung damage occurs as the result of changes in alveolo-capillary permeability.

Accordingly, the term "modulation" refers to increases and decreases in serum pulmonary 15 surfactant levels relative either to a normal reference level (or normal reference level range) or to an earlier surfactant level result determined from the body fluid of said mammal. A normal reference level is the surfactant level from the body fluid of a mammal or group of mammals which do not have any lung injury. Said reference level may be a discrete figure or may be a range of figures. Said reference level may vary between individual classes of 20 surfactant molecules. For example, the normal level of SP-A may differ to the normal level of SP-B or a particular SP-B subunit . Preferably, said modulation is an increase in blood pulmonary surfactant levels.

According to this preferred embodiment there is provided a method of diagnosing lung 25 damage in a mammal said method comprising screening for an increase in pulmonary surfactant levels in the blood of said mammal.

Preferably, said pulmonary surfactant is SP-A, -B, -C or -D and even more preferably SP-B.

- 11 -

In particular, the lung damage may be early stage lung damage and most particularly alveolo-capillary membrane damage.

According to this most preferred embodiment, there is provided a method of diagnosing early 5 stage alveolo-capillary membrane damage in a mammal, said method comprising screening for an increase in SP-B levels in the blood of said mammal.

Although the preferred method is to detect an increase in blood pulmonary surfactant levels, the detection of a decrease in said surfactant levels may be desired under certain 10 circumstances. For example, to monitor improvement in alveolo-capillary membrane morphology during the course of therapeutic treatment of patients presenting with alveolo-capillary membrane damage or to monitor lung maturation in preterm infants with respiratory distress syndrome.

15 Accordingly, another aspect of the present invention provides a method of monitoring for changes in the extent of lung damage in a mammal said method comprising screening for the modulation of pulmonary surfactant levels in the blood of said mammal.

Preferably, said pulmonary surfactant is SP-A, -B, -C or -D and even more preferably 20 SP-B.

In particular, the lung damage may be alveolo-capillary membrane damage.

In a most preferred embodiment there is provided a method of monitoring for an increase in 25 the extent of alveolo-capillary membrane damage in a mammal said method comprising screening for an increase in SP-B levels in the blood of said mammal.

In yet another most preferred embodiment there is provided a method of monitoring for a decrease in the extent of alveolo-capillary membrane damage in a mammal said method 30 comprising screening for a decrease in SP-B levels in the serum of said mammal.

- 12 -

The pulmonary surfactant levels utilised in the method of the present invention, in addition to the analysis of absolute values relative to a normal reference level, may also be analysed relative to one another. For example, lung injury results in a differential change in blood SP-A and SP-B levels such that the ratio of SP-B:SP-A is inversely related to lung functions.

5 These ratios may also be compared to normal reference level ratios.

Accordingly, another aspect of the present invention relates to a method of diagnosing lung damage in a mammal, said method comprising screening of the modulation of pulmonary surfactant level ratios in the blood of said mammal.

10

Reference to "pulmonary surfactant level ratios" should be understood as the ratio of the level of any two or more pulmonary surfactants in a mammal. "Pulmonary surfactant" has the same meaning as hereinbefore defined. The ratio, in a mammal, of one pulmonary surfactant level to another pulmonary surfactant level may be indicative of lung damage.

15

Preferably, said pulmonary surfactant level ratio is a ratio of the SP-B:SP-A levels and more preferably SP-B preproprotein:SP-A.

Even more preferably said modulation is an increase in the ratio.

20

Still more preferably, said increase in SP-B:SP-A or SP-B preproprotein:SP-A ratio is indicative of alveolo-capillary membrane damage.

Yet another aspect of the present invention relates to a method of monitoring for changes in
25 the extent of lung damage in a mammal, said method comprising screening for the modulation of pulmonary surfactant level ratios in the blood of said mammal.

The method of the present invention has widespread applications, including but not limited to, as a non-invasive clinical or diagnostic monitor of lung function or
30 morphological/structural damage (such as the onset of alveolo-capillary membrane damage

or protein retention) due to, for example, an inflammatory response, exposure to a foreign agent, noxious agent, toxic agent, a side effect of an exposure to a therapeutic agent, post-transplant lung rejection, onset of autoimmunity, pulmonary clearance experiment or gaseous exchange impairment and the onset of alveolo-capillary membrane damage of individuals exposed to foreign agent or a noxious or toxic agent such as individuals who smoke or individuals who are involved in occupations such as welding, spray painting, fibreglass manufacture or involving exposure to passive smoking, which may potentially result in lung damage. The method of the present invention also has application in assessment of the lung health status of any individual irrespective of any perceived predisposition or possibility of having acquired a degree of lung damage.

The method of the present invention extends to diagnosing the degree of lung damage in a mammal based upon an analysis of quantitated pulmonary surfactant levels in the blood of said mammal. For example, the degree of increase in blood pulmonary surfactant level is used as an indicator of the degree of lung damage which the mammal has developed.

Acute lung injury (referred to herein as "ALI") may develop following exposure to a number of factors such as, but not limited to, aspiration of gastric contents, pneumonia, sepsis, massive transfusion, multiple trauma and pancreatitis. A smaller number of patients develop more severe lung injury, sometimes referred to as acute or adult respiratory distress syndrome (referred to herein as "ARDS"), which is a more severe form of ALI with a mortality rate of around 50-60%. Prediction of patients who are at high likelihood of developing ARDS would allow, for example, targeting of novel therapies, and use of complex ventilatory strategies, the cost of which might not otherwise be justified.

25

Accordingly, another aspect of the present invention provides a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage, said method comprising screening for the modulation of pulmonary surfactant levels in the blood of said mammal wherein the levels of said pulmonary surfactants are indicative of a predisposition to developing additional lung damage.

- 14 -

The phrase "lung injury factor" should be understood as a reference to any factor which may directly or indirectly cause new lung damage or exacerbate existing lung damage. Examples of said factor include, but are not limited to, mechanical ventilation, hyperoxia, aspiration of gastric contents, pneumonia, sepsis, massive transfusion, multiple trauma and pancreatitis.

5 Lung damage caused by exposure of a mammal to a lung injury factor may or may not be clinically apparent.

The method of the present invention is useful for predicting either those patients, who have been exposed to a lung injury factor, who are likely to develop severe lung injury (and not merely ALI) or those patients, who have developed ALI as a result of exposure to a lung injury factor, who are likely to go on to develop severe lung damage. Accordingly, the phrase "severe lung damage" should be understood in its broadest sense and includes reference to either the development of new lung damage or exacerbation of existing lung damage, such as an increase in its severity. In a particularly preferred embodiment, said 15 mammal has developed ALI due to exposure to a lung injury factor and said severe lung damage is ARDS. Said ALI may or may not be clinically apparent.

According to this preferred embodiment, the present invention provides a method of determining, in a mammal which has developed ALI due to exposure to a lung injury factor, 20 a predisposition to developing ARDS said method comprising screening for the modulation of pulmonary surfactants in the blood of said mammal wherein the levels of said pulmonary surfactant are indicative of a predisposition to developing ARDS.

Most preferably said surfactant is SP-A and/or SP-B.

25

According to this most preferred embodiment, the present invention provides a method of determining, in a mammal which has developed ALI due to exposure to a lung injury factor, a predisposition to the development of ARDS said method comprising screening for the level of SP-A and/or SP-B in the blood of said mammal wherein the level of said SP-A and/or SP- 30 B is indicative of a predisposition to developing ARDS.

- 15 -

Yet another aspect of the present invention provides a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage said method comprising screening for the modulation of pulmonary surfactant level ratios in the blood of said mammal wherein said ratios are indicative of a predisposition to developing
5 severe lung damage.

Without limiting the present invention to any one theory or mode of action, SP-A and SP-B are thought to be surrogate markers for disease severity that may not be detected clinically. Accordingly, reference to screening for a "predisposition" to additional lung damage should
10 be understood in its broadest sense to include both screening for those mammals likely to develop additional lung damage and screening for those mammals who have already developed said additional lung damage but are not yet exhibiting clinical symptomology.

In another aspect of the present invention, the predisposition to developing severe lung damage, such as ARDS, can be determined by correlating the measurement results of multiple factors or clinical parameters of lung function or morphology (referred to herein as "lung clinical parameters"), such as the lung injury score, with surfactant levels. For example, the risk of developing ARDS may be determined utilising a model which correlates SP-A and SP-B levels. In a particular embodiment said method correlates SP-A, SP-B and the lung injury
20 score where $P=0.012$ and $R^2=46\%$. The lung injury score is based upon clinical parameters and is used to summarise clinical severity of illness. Although the lung injury score in isolation may not be predictive of the development of ARDS, it is useful when combined with the surfactant level predictive index.

25 Accordingly, another aspect of the present invention provides a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage said method comprising correlating the modulation of pulmonary surfactant levels in the blood of said mammal with the measurement result of another lung clinical parameter wherein the result of said correlation is indicative of a predisposition to developing severe lung damage.

Preferably, the present invention provides a method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage said method comprising correlating the modulation of pulmonary surfactant levels in the blood of said mammal with the lung injury score wherein the result of said correlation is indicative of a 5 predisposition to developing severe lung damage.

Preferably said mammal has ALI resulting from exposure to a lung injury factor and said severe lung damage is ARDS.

10 Even more preferably said surfactants are SP-A and/or SP-B.

It should be understood that although this aspect of the present invention is exemplified with respect to lung injury score, it is not intended to be limited to an assessment of the lung injury score together with the pulmonary surfactant level. Rather, it should be understood to extend 15 to the correlation of any lung clinical parameter, of which lung injury score is merely an example, together with pulmonary surfactant level.

Screening of pulmonary surfactant levels in serum of a mammal can be achieved via a number 20 of techniques such as functional tests, enzymatic tests or immunological tests. Functional tests may include detecting SP-A or -B by their ability to affect release or re-uptake of surfactant or by detecting host defence properties. SP-C may be detected by measuring associated palmitates. Immunological tests may include contacting a serum sample with an antibody specific for a pulmonary surfactant (or group of pulmonary surfactants) or its derivatives thereof for a time and under conditions sufficient for an antibody-pulmonary 25 surfactant complex to form, and then detecting said complex.

In one particular preferred method the target surfactant molecules in the serum sample are exposed to a specific antibody which may or may not be labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound 30 target may be detectable by direct labelling with an antibody. Alternatively, a second labelled

antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary complex. The complex is detected by the signal emitted by the reporter molecule.

5 By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

10

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however, a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, beta-15 galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the 20 enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present 25 in the sample.

Alternatively, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light 30 energy, inducing a state to excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent

labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength the fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques are both very well established in the art and are 5 particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

The method of the present invention should be understood to include both one off measurements of surfactant levels in a mammal and multiple measurements conducted over a period of time (for 10 example as may be required for the ongoing monitoring of an individual mammal's lung damage status).

Another aspect of the present invention provides a diagnostic kit for assaying serum samples comprising in compartmental form a first compartment adapted to contain an agent for detecting 15 pulmonary surfactant and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment. Further compartments may also be included, for example, to receive a biological sample. The agent may be an antibody or other suitable detecting molecule.

20 Further features of the present invention are more fully described in the following Examples. It is to be understood, however, that this detailed description is included solely for the purposes of exemplifying the present invention. It should not be understood in any way as a restriction on the broad description of the invention as set out above.

25 Reference to SP-A and SP-B in the following examples should be understood as a reference to immuno-reactive SP-A and SP-B.

- 19 -

EXAMPLE 1

Sample Preparation and Storage

Blood was immediately centrifuged in tubes (Disposable Products, Sydney, Australia) 5 containing lithium heparin (plasma) or clot retraction accelerator (serum) at 5,000 rpm for 5 min at room temperature (Megafuge; Heraeus-Christ, Osterode, Germany). Samples stored at -20°C for batch analysis.

EXAMPLE 2

Primary Antibody Preparation

10

SP-A and SP-B were purified from the lavage fluid of patients with alveolar proteinosis. Each protein was emulsified with Freund's complete adjuvant (Difco Laboratories, Detroit, MI) and injected subcutaneously into 3 New Zealand white rabbits. The immunizations were 15 boosted with SP-A or SP-B emulsified in Freund's incomplete adjuvant (Difco Laboratories). The rabbits were exsanguinated and IgG precipitated from the serum using 50% (vol/vol) saturated ammonium sulfate. The IgG was reconstituted to the original serum volume in 136.8 mM sodium chloride, 8.1 mM disodium hydrogen phosphate, 2.6 mM potassium chloride, 0.7 mM potassium dihydrogen phosphate containing 0.02% sodium azide and 20 0.05% (vol/vol) Tween 20 (PBST) and immunoabsorbed overnight at 4°C against 200 ml of cross-linked, normal human serum. In order to remove any specificities against soluble blood group A antigenic determinants, the cross-linked serum was prepared from pooled blood comprising equal portions of plasma from five subjects with blood groupings: A (+ve), A (-ve), AB (+ve), O (+ve) and O (-ve). Non-adsorbed components were isolated following 25 centrifugation at 4°C at 8,000 x g (max) for 1 h and the immunoabsorption procedure repeated using fresh human serum immunoabsorbent. Finally, the antibodies were filtered through a 0.2 µm Acrodisc filter (Sterile Acrodisc; Gelman Sciences; Ann Arbor, MI; #4192).

30

- 20 -

Both antibodies react strongly with their antigens in both their native and reduced states. The antibody against SP-B also reacts with its processing intermediate and its proprotein in addition to the mature peptide.

5

EXAMPLE 3 ELISA

SP-A and -B were determined by ELISA inhibition assays using SP-A and SP-B purified from alveolar proteinosis lavage fluid as standard.

10

Samples were assayed in a blind randomized manner. In order to free the SP-A and -B from any associated plasma or surfactant components, all samples were treated in the following manner. 125 μ l aliquots were diluted in 500 μ l of 10 mM Tris, 1 mM EDTA containing 0.25% BSA (pH 7.4). After vortexing at room temperature for 10 min, 125 μ l of solution 15 containing 3% SDS and 12% Triton X-100 (v/v) was added to each sample. The samples were again vortexed for 10 min and surfactant protein concentration determined using an ELISA inhibition assay.

The SP-A and SP-B assays were performed in 2 parts. Costar ELISA plates (Costar, 20 Cambridge, MA; #2595) were coated overnight at 4°C with purified SP-A or -B (1 μ g/ml) in a solution containing 15 mM sodium carbonate, 35 mM sodium bicarbonate and 0.02% sodium azide (pH 9.6). The coated plates were washed with PBST prior to use.

In a separate ELISA plate dilutions of the samples and standards (which were routinely 25 included in each plate) were incubated with aliquots of the respective primary antibody. Each treated sample was assayed at four 2 - fold dilutions in PBST containing 0.25% BSA (PBST/BSA). Standard curves comprising eight 2 - fold serial dilutions in PBST/BSA (SP-A: 1.95 ng/ml to 250 ng/ml; SP-B: 7.8 ng/ml to 1.0 μ g/ml) were constructed. Samples were assayed in duplicate while standards were assayed in quadruplicate.

30

- 21 -

After 90 min aliquots were transferred to the plates coated with SP-A and SP-B and incubated at room temperature for an additional 90 min. These plates were then washed with PBST and incubated at room temperature for 90 min with aliquots of alkaline phosphatase-conjugated sheep anti-rabbit polyclonal IgG (Silenus Laboratories) diluted in PBST/BSA. After washing 5 with PBST the plates were developed at room temperature with 15 mM disodium p-nitrophenyl phosphate (Sigma 104 phosphatase substrate tablets; Sigma Chemical Co; St Louis, MO) in 1.0 M diethanolamine and 0.5 mM magnesium chloride. At ~1 h the absorbance of the substrate was measured at 405 nm using a Dynatech MR5000 reader (Dynatech Laboratories, Chantilly, VA). An AssayZap program (Biosoft, Ferguson, MO) 10 was used to generate a standard curve and to compute the concentration of the surfactant protein in each sample based on their immunoreactivity.

Statistics

15 Results are expressed as mean \pm SE. Non-parametric analyses were used since we have no reason to assume that the data is normally distributed. The Mann-Whitney U Test or the Wilcoxon Matched Pairs Sign Rank Test was used for all comparisons.

EXAMPLE 4

20

Normal Plasma Surfactant Protein Levels and Smoking

Cigarette smoking has been implicated as a factor causing lung damage. This includes damage to the airway and the lung parenchyma, and may manifest as a broad range of conditions including bronchitis, emphysema and some lung cancers. However, many 25 smoking subjects have no clinically evident lung damage and are asymptomatic. Consequently a 'normal plasma surfactant protein level' may need to be described for non-smokers and smokers with the 'normal smoking level' describing asymptomatic lung damage.

Since cigarette smoking may acutely and reversibly increase lung epithelial permeability through smoke mediated release of vasoactive neuropeptides (tachykinins) from sensory nerves in the airways (Germonpre *et al*, 1995; Geppetti *et al*, 1993; Lei *et al*, 1993; Nadel & Borson, 1991), smokers are requested to refrain from smoking for at least 4 h prior to screening. Two ml of peripheral blood is drawn from an antecubital vein and centrifuged in lithium heparin tubes at 5,000 rpm for 5 min at room temperature (Megafuge; Heraeus-Christ; Osterode, Germany) immediately following collection.

Blood was sampled from 66 asymptomatic adults not known to have any lung disease. The subjects age, sex and smoking history were noted. The results are shown in Table 1.

Table 1

	Non-smokers	Smokers	P-value
Age (years)	30.4 ± 1.7	33.7 ± 1.3	NS
Sex (M/F)	16/19	16/15	NS
SP-A (ng/ml)	248.4 ± 14.1	242.3 ± 29.8	NS
SP-B (ng/ml)	2026.9 ± 91.8	3046.2 ± 209.1	<0.001

(means \pm SE, Mann-Whitney U-test)

Thirty one subjects had smoked 20.1 ± 2.7 pack/years of cigarettes, and this correlated with their SP-B levels with an R^2 of 33% and a P-value=0.0005. The 95% confidence intervals from these data for SP-A were 219.7-277.1 (ng/ml) for non-smokers and 181.4-303.2 (ng/ml) for smokers, and for SP-B 1840-2213 (ng/ml) for non-smokers and 2619-3473 (ng/ml) for smokers.

25

The plasma SP-B level is elevated in asymptomatic smokers compared to asymptomatic non-smokers, consistent with impaired lung health in smokers. This supports the claim that the plasma SP-B level is an extremely sensitive marker of lung health. The 95% confidence intervals may be used to estimate a plasma level of each surfactant protein that is elevated, indicating lung damage, for that cohort. Subsequent data may refer to elevated levels in

- 23 -

comparison with this data or an elevation from the baseline plasma level from longitudinal studies in an individual subject.

EXAMPLE 5

5 Exercise-induced Impairment of the Alveolocapillary Barrier in Humans

Eighteen male subjects (mean \pm SE, age: 18 to 29 yr, 24.3 \pm 0.80 yr; height: 162 to 188 cm, 178.6 \pm 1.72 cm; weight: 53 to 95 kg, 75.9 \pm 2.61 kg), all nonsmokers, arrived in the pulmonary function laboratory between 7.00 and 8.00 am, after fasting from midnight.

10 Single peripheral blood samples were drawn from an antecubital vein from half of the subjects. The remaining nine subjects were subjected to an exercise regimen and blood sampled immediately afterwards. One week later the subject groups were reversed. The procedure was repeated on 13 of the subjects ~8 wk later.

15 Acute Exercise Procedure

Subjects were equipped with an ear pulse oximeter (Criticare 504-USP, CSI-USA, Waukesha, WI) for monitoring heart rate. The subjects cycled at 60 rpm (Ergometry System Model 380B; Siemens-Elema AB, Sona, Sweden) and the load was increased to bring heart rate to 20 approximately 90% of the theoretical maximal heart rate, calculated as 210-(0.6 x age), within 10 min. Cycling continued for a further 20 min, and the load was continuously adjusted so as to maintain heart rate as close as possible to this value. In all cases this involved the gradual reduction of load over the period.

25 Results

Serum SP-B levels are significantly (<0.01, n=31; Wilcoxon Matched-Pairs Signed-Rank test) elevated after exercise (rest: 1656.5 ng/ml \pm 94.46; exercise; 1899.8 ng/ml \pm 128.35; mean \pm SE).

- 24 -

In humans pulmonary capillary pressure may peak at 35 mmHg during strenuous exercise and this is sufficient to impair the integrity of the blood-gas barrier. Those findings are consistent with this and illustrate that a rapid rise in pulmonary capillary pressure may produce stress failure in the pulmonary capillaries and increase alveolo-capillary permeability.

5

By way of contrast, horses have comparatively a far greater cardiac output, furthermore, thoroughbreds are selectively bred to maximize performance. Consequently, pulmonary capillary pressure may reach 200 mmHg at the base of their lungs during strenuous exercise. Although the blood-gas barrier of horses is more resistant to stress failure than that of many 10 other mammals, faced with these pressures it is hardly surprising that ~90% of 5 yr old thoroughbreds have suffered at least one episode of gross pulmonary haemorrhage, with an appreciable cost to the racing industry. Circulating SP-A & -B are sensitive markers of hydrostatic pressure-induced lung damage.

15 Since during strenuous exercise, pulmonary vascular pressures are elevated and result in increased lung water and increased alveolo-capillary permeability in race horses, this results in rupture of pulmonary blood vessels which manifest as blood in the alveolos. Blood or blood product surfactant protein levels are monitored during the training, racing and during recovery from exercise induced lung damage.

20

EXAMPLE 6

Acute Respiratory Failure

Acute respiratory failure may be due to multiple causes such as cardiac pulmonary edema, 25 polytrauma, multiple transfusion, sepsis or serious infection, aspiration of gastric contents, pneumonia, disseminated intravascular coagulation and pancreatitis.

Blood was sampled from 83 patients in the Critical Care Unit at Flinders Medical Centre, the plasma isolated and stored at -20°C prior to analysis. Their age, sex, and lung injury score 30 (LIS)¹ derived from a chest radiograph score, the partial pressure of oxygen to inspired

oxygen ratio ($\text{PaO}_2/\text{FiO}_2$ ratio), the amount of positive end-expiratory pressure and the respiratory system compliance was calculated. Ten subjects were mechanically ventilated for reasons other than respiratory failure, and were thought to have normal lung function. The remaining 73 patients had acute respiratory failure and are subdivided depending upon the
5 underlying cause.

Results

Table 2 (means \pm SE)

	Number	Male/ Female	Age	Lung Injury Score	Plasma SP-A (ng/ml)	Plasma SP-B (ng/ml)
10						
Ventilated controls	10	7/3	36 \pm 8	0.3 \pm 0.2	227 \pm 30	1998 \pm 169
15						
Cardiac pulmonary edema	10	7/3	36 \pm 8	0.3 \pm 0.2	268 \pm 22	3646 \pm 635
20						
Polytrauma	4	4/0	33 \pm 4	1.3 \pm 0.2	444 \pm 108	4174 \pm 1197
25						
Multiple transfusion	9	8/1	70 \pm 3	2.1 \pm 0.2	368 \pm 41	3456 \pm 384
30						
Sepsis	14	9/5	65 \pm 3	2.3 \pm 0.3	467 \pm 233	4373 \pm 819
35						
Aspiration	13	9/4	70 \pm 3	2.3 \pm 0.1	500 \pm 67	8110 \pm 1338
40						
Pneumonia	12	8/4	58 \pm 5	2.2 \pm 0.3	528 \pm 86	9725 \pm 1735
45						
Disseminated intravascular coagulation	2	1/1	36 \pm 18	2.5 \pm 0.5	452 \pm 232	6099 \pm 4312
50						
Pancreatitis	6	4/2	49 \pm 4	2.1 \pm 0.2	414 \pm 119	4768 \pm 1696
55						
Liver failure	3	1/2	31 \pm 6	3.4 \pm 0.3	531 \pm 106	7407 \pm 2627

The ventilated control subjects had normal plasma SP-A and SP-B levels (Table 2). However, there are elevated plasma levels in a wide variety of causes of acute respiratory failure. The highest SP-A and SP-B levels were generally found in patients with acute respiratory failure due to aspiration pneumonia or pneumonia, both direct causes of lung injury. The lowest, but still elevated levels of SP-A and SP-B were found in patients with cardiac pulmonary edema. This is consistent with elevated plasma levels of these proteins representing an increase in alveolo-capillary permeability, and that this elevation is generally greatest in direct causes of lung injury and a lesser elevation in lung injury due to an elevation in pulmonary hydrostatic pressure, that is an indirect cause of lung injury.

10

EXAMPLE 7**Monitoring of therapeutic, lung toxic drugs - for example methotrexate**

Methotrexate is a commonly used immuno suppressive drug for the treatment of a variety of conditions including rheumatoid arthritis. However, a side effect of methotrexate is lung damage which has, to date, been detected by symptoms such as changes in blood gases or sophisticated lung function tests. Said methods only detect advanced lung damage. Blood or blood product surfactant protein levels are used to monitor the safety of methotrexate therapy by detecting any increase in alveolo-capillary permeability. Monitoring comprises a preliminary test followed by intermittent (daily, weekly or monthly) testing.

EXAMPLE 8**Monitoring of Bleomycin Treated Patients**

Bleomycin is an anti-cancer or cytotoxic drug known to cause pulmonary toxicity. Risk factors for bleomycin-induced lung injury include increasing dose, concurrent use of other cytotoxic drugs, radiotherapy and supplemental oxygen. Three main mechanisms are thought to account for lung injury. Direct cytotoxicity from reactive oxygen species causes a permeability pulmonary edema, similar to acute lung injury (ALI). Lung injury may also occur due to hypersensitivity or idiosyncratic reactions. None of the other cytotoxic drugs

alone and used in the doses given to the patients described commonly cause pulmonary toxicity.

Listed in Table 3 are four patients who were treated with bleomycin and other cytotoxic drugs. None of the patients had any respiratory symptoms, none had known lung involvement with cancer and all were non-smokers. Blood was sampled at rest and the plasma frozen at -20°C until assayed.

REDACTED

Table 3
Chemotherapy data

5	Diagnosis	Age	Sex	Smoking history	PFT's ¹	Bleomycin dose (units)	Other cytotoxics	SP-A (ng/ml)	SP-B (ng/ml)
Testicular cancer ²	39	M		ceased 15 years	60	cisplatin 450 mg etoposide 2.2 g		360.2	1547.9
Hodgkin's lymphoma ³	23	M		never	90	doxorubicin 450 mg vinblastine 110 mg dacarbazine 6.8 g		174.3	1730.0
Non-Hodgkin's lymphoma	74	M		never	15	cyclophosphamide 1g etoposide 100 mg procarbazine 100 mg prednisolone 75 mg		265.5	2598.2
Non-Hodgkin's lymphoma	60	F		never	30	cyclophosphamide 2.2 g etoposide 390 mg procarbazine 1 g prednisolone 1 g	413.6	1382.6	
	15								

¹Pulmonary function tests include lung volumes, transfer factor and bronchodilator responses were normal prior to starting cytotoxic chemotherapy.

²A week later a further 30 units of bleomycin his SP-A and SP-B levels were still elevated but had fallen to 295.5 and 1199.8 ng/ml respectively

³Two weeks after a further cycle of chemotherapy which included a further 18 units of bleomycin his SP-A level had risen to 339.9 ng/ml and his SP-B had risen to 5512.8 ng/ml.

Results

- The plasma SP-B level in patient 3 is elevated, but the SP-B levels in the other patients are normal. This is consistent with individual variability to the lung toxic effects of bleomycin.
- Patient 2: The elevation of SP-A and SP-B with a further dose of bleomycin (see footnote 3) is consistent bleomycin-induced lung damage leading to an increase in alveolo-capillary permeability and an increase in the plasma surfactant protein levels. This indicates that surfactant protein levels may be used to monitor the administration of lung toxic drugs.
- Patient 1: The fall in SP-A and SP-B after further chemotherapy is consistent with repair and resolution of bleomycin-induced lung damage. This indicates that surfactant protein levels may be used to monitor resolution of lung damage due to a toxic drug.

EXAMPLE 9

Radiotherapy Induced Lung Damage

Radiation therapy which either targets or inadvertently exposes the lung may result in lung damage. While this is often relatively asymptomatic, some patients become symptomatic and may develop respiratory failure. This occurs in the weeks following initiation of treatment. Surfactant protein levels are used to monitor this lung damage allowing individualisation of radiotherapy dose and/or frequency.

Case 1: Blood was sampled from a 19 year old non-smoking male 2 weeks after a course of radiotherapy for Hodgkins lymphoma. He had no respiratory symptoms and prior chemotherapy was not thought to be lung toxic. His plasma SP-A was elevated at 416.9 ng/ml as was SP-B at 4020.6 ng/ml.

- 30 -

Case 2: Blood was sampled from a 57 year old woman 3 weeks after radiotherapy for a squamous cell carcinoma of the lung. She had ceased smoking recently and had no change in her respiratory symptoms. Prior chemotherapy was not thought to be lung toxic. Her plasma SP-A was markedly elevated at 963.6 ng/ml and her SP-B was elevated at 2742.2 ng/ml.

Symptoms from radiotherapy induced lung toxicity commonly occur some weeks after treatment. The elevation in surfactant proteins in both patients is consistent with the elevation being due to radiotherapy induced lung damage and an increase in alveolo-capillary permeability. Consequently, surfactant protein levels are used to monitor radiotherapy, to individualise therapy and to monitor rescue treatments such as growth factors.

EXAMPLE 10

15 Monitoring herbicide induced lung damage

Paraquat is a widely used herbicide that destroys the lipid cell membrane through production of oxygen radicals. This is also thought to be the mechanism of toxicity, predominantly pulmonary, in humans. Typically acute lung injury develops some days following ingestion 20 and this usually progresses to fatal respiratory failure due to the development of the acute respiratory distress syndrome with marked pulmonary fibrosis.

Blood was sequentially sampled from a patient following ingestion of paraquat for measurement of circulating surfactant proteins and for documentation of blood oxygenation. 25 In the figure the initial blood oxygenation to inspired oxygen ratio ($\text{PaO}_2/\text{FiO}_2$ ratio) is normal and remains unchanged until 64 hours following presentation. The sudden fall in the $\text{PaO}_2/\text{FiO}_2$ ratio is evidence of lung damage. The plasma SP-B level was also normal at presentation by suddenly increased at 54 hours following ingestion, 10 hours before the change in blood oxygenation.

- 31 -

This data demonstrates that surfactant proteins are early markers of lung damage, and that this precedes clinical diagnosis of lung damage (Figure 1).

EXAMPLE 11

5 Prediction of Severe Lung Damage

Following a predisposing cause patients may develop acute lung injury (ALI) and require respiratory support for acute respiratory failure. When this progresses to more severe lung damage it may be termed acute respiratory distress syndrome (ARDS). Prediction of which 10 patient will develop ARDS has many therapeutic implications.

43 patients treated in the critical Care Unit and Flinders Medical Centre had blood sampled within 12 hours of developing ALI which was defined as a lung injury score (LIS) < 2.5. Their sex, age, LIS and the development of ARDS (LIS > 2.5) were documented. Plasma 15 was isolated and frozen at -20C until assayed. The data is presented as mean \pm SE, and the data compared with a Mann-Whitney U-test.

Results

20 **Table 4**

	Does not develop ARDS	Develops ARDS	P-value
Age	60 ± 4	61 ± 3	NS
Male/Female	17/7	11/8	NS
LIS	1.7 ± 0.1	1.9 ± 0.1	NS
25 SP-A (ng/ml)	393 ± 36	514 ± 55	NS
SP-B (ng/ml)	4162 ± 502	8222 ± 1319	0.017

- 32 -

The plasma level of SP-B is significantly higher in subjects with ALI who will develop ARDS than those who do not (Table 4). Since the LIS is no different between the two groups, and there is no difference in age or sex distribution, this cannot be predicted on clinical grounds. This indicates that surfactant protein levels may be used to predict the development of severe lung injury.

EXAMPLE 12

Surfactant Protein Ratios

10 The ratio of surfactant components is useful in understanding, diagnosing and monitoring disease processes. As an example Table 5 lists SP-B/A ratios for some of the patient groups studied.

Table 5

	Number	Male/Female	Age	Lung Injury	SP-B/A Ratio
				Score	
	Non-smokers	35	16/19	30.4 ± 1.7	8.6 ± 0.5
	Smokers	31	16/15	33.7 ± 1.3	15.2 ± 1.6
5	ALI only	24	17/7	60 ± 4	11.6 ± 1.2
	Pre-ARDS	19	11/8	61 ± 3	16.8 ± 2.7
	Ventilated controls	10	7/3	36 ± 8	0.3 ± 0.2
	Cardiac	10	7/3	36 ± 8	0.3 ± 0.2
10	pulmonary edema				13.8 ± 2.2
	Polytrauma	4	4/0	33 ± 4	9.4 ± 1.6
	Multiple transfusion	9	8/1	70 ± 3	10.4 ± 1.5
15	Sepsis	14	9/5	65 ± 3	9.9 ± 1.3
	Aspiration	13	9/4	70 ± 3	17.5 ± 2.6
	Pneumonia	12	8/4	58 ± 5	21.6 ± 4.0
	Disseminated intravascular	2	1/1	36 ± 18	2.5 ± 0.5
20	coagulation				15.9 ± 2.0
	Pancreatitis	6	4/2	49 ± 4	11.5 ± 1.8
	Liver failure	3	1/2	31 ± 6	11.8 ± 7.3

25 The SP-B/A ratio for non-smokers is the same as that for ventilated control subjects, however the SP-B/A ratio is higher for smokers. This is consistent with SP-B levels reflecting leakage through smaller pores in the alveolo-capillary membrane. There is also a marked elevation

- 34 -

in the SP-B/A ratio in the direct causes of lung damage such as pneumonia and aspiration compared to the indirect causes such as sepsis. This is consistent with a greater increase in permeability in this group. Consequently the SP-A/B ratio can be used in addition to the absolute surfactant levels.

5

EXAMPLE 13

Monitoring Vascular SP-A and SP-B Levels as Surrogate Markers of Pulmonary Surfactant Status

10 Non-pulmonary vascular and extravascular levels of SP-A & -B will depend not only on the alveolo-capillary permeability, but also on the alveolar levels.

Primary alveolar proteinosis is a chronic disease of unknown pathogenesis characterised by the diffuse accumulation of excess surfactant in the airspaces. Patients are usually less than 15 years old with an appreciable proportion adolescents and infants. Although whole-lung lavage has become standard therapy, the clinical course varies markedly. It is thought that surfactant synthesis and secretion in primary alveolar proteinosis patients is normal and that surfactant accumulation in the alveolus arises through an impairment in its clearance.

20 *Congenital alveolar proteinosis* is also characterised by the diffuse accumulation of excess surfactant in the airspaces. As distinct from primary alveolar proteinosis, there are now a number of established cause for the congenital phenotype. These include, but are not limited to, the lack of expression of the GM-CSF Receptor beta-common chain and molecular defects in the SP-B gene.

25

Single peripheral blood samples were drawn from an antecubital vein from 12 patients (30 yr \pm 2.7; mean \pm SE) diagnosed with primary alveolar proteinosis. Patients were diagnosed as idiopathic both clinically and on the basis of either transbronchial or open lung biopsy.

30

Single peripheral blood samples were also drawn from an antecubital vein from 3 infants (< 1 yr) diagnosed with congenital alveolar proteinosis. The infants expressed normal GM-CSF Receptor components and did not have the SP-B defect molecularly or on immunohistochemistry.

5

Results

Serum SP-A and SP-B were greatly elevated in patients with primary or congenital alveolar proteinosis (all groups $p < 0.001$; Mann-Whitney U test) compared to normal. (Table 6).

10

Table 6

	Primary Alveolar Proteinosis	Congenital Alveolar Proteinosis
SP-A	1440.5 ng/ml \pm 259.05	3096.2 \pm 834.17
SP-B	17845.2 ng/ml \pm 3065.16	39928.1 \pm 5884.91
(mean \pm SE		

Circulating SP-A and -B are greatly elevated in patients with primary or non-SP-B deficient-
20 congenital alveolar proteinosis. Since alveolo-capillary permeability is normal in these patients this illustrates that circulating SP-A & -B mark changes in pulmonary surfactant levels.

Approximately 30% of primary alveolar proteinosis cases resolve spontaneously, some require
25 multiple lavage over extended periods, while others progress to disseminated lung disease. If left untreated ~30% of patients progress to dyspnea, hypoxemia and death. In the absence of lung transplant, the prognosis for infants with congenital alveolar proteinosis is poor.

- 36 -

Currently, the severity of alveolar proteinosis is only poorly reflected by indirect parameters such as blood oxygenation. Circulating surfactant protein levels offer a direct non-invasive method of monitoring this condition. The test also has particular utility in the diagnosis of congenital forms of the condition where SP-B may, or may not, be present. In addition, 5 circulating surfactant protein levels offer a direct non-invasive method of monitoring surfactant levels and lung maturation in pre-term infants with respiratory distress syndrome.

EXAMPLE 14

The Monitoring of SP-A and -B Levels in Both Vascular and Extravascular Fluids

10

Single pleural fluid and matching bloods were collected from 88 patients who had diagnostic of therapeutic thoracentesis (63 ± 14 yr; mean \pm SE). The study population included patients with neoplasia (metastatic carcinoma, hematologic malignancy, and mesothelioma), inflammatory pleural effusion (parapneumonic, postsurgical, emphysema, subphrenic abscess, 15 collagen vascular disease, as well as other various causes), congestive heart failure, and patients with cirrhosis and hydrothorax.

Results

20 Pleural SP-A and SP-B levels are significantly elevated (both $p < 0.001$, $n = 88$; Wilcoxon Matched-Pairs Signed-Rank test) compared to the matching serum samples (Table 7). Both serum SP-A and -B significantly relate to the pleural levels (SP-A; $p < 0.001$, $r_s = 0.57$, $n = 88$; SP-B; $p < 0.001$ $r_s = 0.4$).

25

Table 7

	mean \pm SE
	Serum SP-A 290.5 ng/ml \pm 22.36
5	Serum SP-B 2599.9 ng/ml \pm 165.6
	Pleural Serum SP-A 632.9 ng/ml \pm 154.91
	Pleural Serum SP-B 4877.8 ng/ml \pm 685.76

10 Although the epithelium and endothelium generally restricts the movement of molecules larger than albumin (M_r 67kD, hydrodynamic radius ~3.5nm), proteins diffuse down their concentration gradients from the lung alveolar hypophase and between vascular and extravascular compartments. The levels of both vascular, and extravascular, SP-A and -B are sensitive markers of alveolo-capillary permeability and lung health.

15 Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this
20 specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

BIBLIOGRAPHY

Doyle, I.R., Jones, M.E., *et al.*, *Am. J. Respir. Crit. Care. Med.* 149:1619-1627 (1994)

Doyle, I.R., Bersten, A.D. and Nicholas, T.E., *Am. J. Respir. Crit. Care Med.* 156:1217-1219 (1997)

Geppetti, P., Bertrand, C., *et al.*, *Br. J. Pharm.* 108:646-50 (1993)

Germonpre, P.R., Joos, G.F., *et al.*, *329:185-203 (1995)*

Holm, B.A., and Notter, R.H., *J. Appl. Physiol.* 63:1434-1442 (1987)

Jefferies, A.L., Kawano, T., Mori, S., and Burger R., *J. Appl. Physiol.* 64:5620-5628 (1988)

Johansson, J., Curstedt, T. and Jornvall, H., *Biochemistry* 30:6917-6921 (1991)

Lei, Y.H., Barnes, P.J. *et al.*, *Eur. J. Pharmacol.* 239:257-9 (1993)

Longo, M.L., Waring, A. and Zasadzinski, A.N., *Biophys. J.* 63:760-773 (1992)

Nadel, J.A. and Borson, D.B. *Am. Rev. Respir. Dis.* 143:S33-36 (1991)

Nicholas, T.E., Bar, H.A., Power, J.H.T. and Jones, M.E. *Amer. J. Physiol.* 259:L238-L246 (1990)

Nicholas, T.E., *NIPS.* 8:12-8 (1993)

- 39 -

, Said, S.I., Avery, M.E., Davis, R.K., Banerjee, C.M., El-Gohary, M., *J. Clin. Invest.* 44:458-464 (1965)

Staub, N.C. and Hyde, R.W. *et al. Am. Rev. Respir. Dis.* 141:1071-1077 (1990)

Voss, T., Eistetter, H., Schäfer, K.P. and Engel, J., *J. Mol. Biol.* 201:219-227 (1988)

Weaver, T.E. and Whitsett, J.A., *Am. J. Physiol.* 257:L100-L108 (1989)

Yogalingam, G., Doyle, I.R., *et al., Am. J. Physiol.* 14:L320-L330 (1996)

CLAIMS:

1. A method of diagnosing lung damage in a mammal said method comprising screening for the modulation of pulmonary surfactant levels in the body fluid of said mammal.
2. A method according to claim 1, wherein said modulation is an increase.
3. A method according to claim 2, wherein said lung damage is early stage lung damage.
4. A method according to claim 3, wherein said early stage lung damage is alveolo-capillary membrane damage.
5. A method according to any one of claims 1 to 4, wherein said pulmonary surfactant is any one or more of SP-A, SP-B, SP-C or SP-D.
6. A method according to claim 5, wherein said pulmonary surfactant is SP-B.
7. A method according to any one of claims 1 to 6, wherein said body fluid is blood.
8. A method of monitoring for changes in the extent of lung damage in a mammal, said method comprising screening for the modulation of pulmonary surfactant levels in the body fluid of said mammal.
9. A method according to claim 8, wherein said lung damage is alveolo-capillary membrane damage.
10. A method according to claim 8 or 9, wherein said pulmonary surfactant is any one or more of SP-A, SP-B, SP-C or SP-D.
11. A method according to claim 10, wherein said pulmonary surfactant is SP-B.

- 41 -

12. A method according to any one of claims 8 to 11, wherein said body fluid is blood.
13. A method of diagnosing lung damage in a mammal, said method comprising screening for the modulation of pulmonary surfactant level ratios in the body fluid of said mammal.
14. A method according to claim 13 wherein said pulmonary surfactant level ratio is the SP-B:SP-A ratio.
15. A method according to claim 14 wherein said modulation is an increase.
16. A method according to claim 15 wherein said lung damage is alveolo-capillary membrane damage.
17. A method according to claim 16 wherein said alveolo-capillary membrane damage is early stage alveolo-capillary membrane damage.
18. A method according to any one of claims 13 to 17 wherein said body fluid is blood.
19. A method of monitoring for changes in the extent of lung damage in a mammal, said method comprising screening for the modulations of pulmonary surfactant level ratios in the body fluid of said mammal.
20. A method according to claim 19 wherein said pulmonary surfactant level ratio is the SP-B:SP-A ratio.
21. A method according to claim 19 or 20 wherein said body fluid is blood.

22. A method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage, said method comprising screening for the modulation of pulmonary surfactant levels in the body fluid of said mammal wherein the level of said pulmonary surfactant is indicative of a predisposition to developing severe lung damage.
23. A method according to claim 22, wherein said modulation is an increase.
24. A method according to claim 23, wherein said mammal has developed acute lung injury due to exposure to a lung injury factor and said severe lung damage is acute respiratory distress syndrome.
25. A method according to any one of claims 22 to 24, wherein said pulmonary surfactant is SP-A, SP-B, SP-C or SP-D.
26. A method according to claim 25, wherein said pulmonary surfactant is SP-B.
27. A method according to any one of claims 22 to 26, wherein said body fluid is blood.
28. A method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage said method comprising screening for the modulation of pulmonary surfactant level ratios in the body fluid of said mammal wherein said ratios are indicative of a predisposition to developing severe lung damage.
29. A method according to claim 28 wherein said body fluid is blood.

30. A method of determining, in a mammal exposed to a lung injury factor, a predisposition to developing severe lung damage, said method comprising correlating the modulation of pulmonary surfactant levels in the body fluid of said mammal with the measurement result of another lung clinical parameter wherein the result of said correlation is indicative of a predisposition to developing severe lung damage.
31. A method according to claim 30, wherein said lung clinical parameter is the lung injury score.
32. A method according to claim 30 or 31, wherein said pulmonary surfactant is one or more of SP-A, SP-B, SP-C or SP-D.
33. A method according to claim 32, wherein said pulmonary surfactant is SP-B.
34. A method according to any one of claims 30 to 33, wherein said body fluid is blood.
35. A method according to any one of claims 1 to 34, wherein said mammal is a human.
36. A diagnostic kit for screening body fluid samples comprising in compartmental form a first compartment adapted to contain an agent for detecting pulmonary surfactant and a second compartment adapted to contain reagents used for facilitating the detection by the agent in the first compartment.

09/486703

WO 99/13337

PCT/AU98/00723

1/1

Oxygenation and plasma SP-B levels following paraquat ingestion




FIGURE 1

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A METHOD OF DIAGNOSIS

(Attorney Docket No. 017227/0157)

the specification of which (check one)

is attached hereto.

was filed on September 4, 1998 as United States Application Number or PCT International Application Number PCT/AU98/00723 and was amended on _____ (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
PO 8999	Australia	05/September/1997	YES	
PO 5062	Australia	04/August/1998	YES	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number

I HEREBY APPOINT the following registered attorneys and agents of the law firm of FOLEY & LARDNER to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith:

STEPHEN A. BENT
DAVID A. BLUMENTHAL
BETH A. BURROUS
ALAN I. CANTOR
WILLIAM T. ELLIS
JOHN J. FELDHAUS
PATRICIA D. GRANADOS

Reg. No. 29,768
Reg. No. 26,257
Reg. No. 35,087
Reg. No. 28,163
Reg. No. 26,874
Reg. No. 28,822
Reg. No. 33,683

JOHN P. ISACSON	Reg. No. <u>33,715</u>
MICHAEL D. KAMINSKI	Reg. No. <u>32,904</u>
LYLE K. KIMMS	Reg. No. <u>34,079</u>
KENNETH E. KROSIN	Reg. No. <u>25,735</u>
JOHNNY A. KUMAR	Reg. No. <u>34,649</u>
GLENN LAW	Reg. No. <u>34,371</u>
PETER G. MACK	Reg. No. <u>26,001</u>
BRIAN J. MC NAMARA	Reg. No. <u>32,789</u>
SYBIL MELOY	Reg. No. <u>22,749</u>
RICHARD C. PEET	Reg. No. <u>35,792</u>
GEORGE E. QUILLIN	Reg. No. <u>32,792</u>
COLIN G. SANDERCOCK	Reg. No. <u>31,298</u>
BERNHARD D. SAXE	Reg. No. <u>28,665</u>
CHARLES F. SCHILL	Reg. No. <u>27,590</u>
RICHARD L. SCHWAAB	Reg. No. <u>25,479</u>
ARTHUR SCHWARTZ	Reg. No. <u>22,115</u>
HAROLD C. WEGNER	Reg. No. <u>25,258</u>



and I request that all correspondence be directed to:

Stephen A. Bent
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

Telephone: (202) 672-5404
Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor	<u>Ian Ross DOYLE</u>
Residence	<u>Marino, AUSTRALIA</u>
Citizenship	<u>Australia</u>
Post Office Address	<u>11 Trumara Road, Marino, South Australia, Australia 5049</u>
<input checked="" type="checkbox"/> Inventor's signature	
<input checked="" type="checkbox"/> Date	

Name of second inventor

Andrew David BERSTEN

Residence

Seacliff, AUSTRALIA


Citizenship

Australia

Post Office Address

33 Marine Parade, Seacliff, South Australia,
Australia 5049

Inventor's signature


18/5/00

Date

Name of third inventor

Terence Evan NICHOLAS

Residence

Bedford Park, Australia

Citizenship

Australia

Post Office Address

31 Malcolm Street, Bedford Park, South Australia,
Australia 5042

Inventor's signature

Date

SEARCHED SERIALIZED INDEXED FILED